



TIRmed Pharma Strengthens Partnership with Zelmic Ahead of Clinical Studies in Atopic Dermatitis

TIRmed Pharma, a biotechnology company developing innovative treatments for autoimmune skin diseases, has expanded its collaboration with Zelmic, a leading specialist in formulation development. The partnership covers GMP development and manufacturing of TIRmed's topical drug candidate TIR-C for the treatment of atopic dermatitis (eczema), aiming to ensure high product quality ahead of upcoming clinical trials.



TIRmed Pharma is developing a new treatment for atopic dermatitis, with the goal of offering patients an effective therapy with fewer side effects and easier administration. The treatment targets the underlying causes of the disease rather than merely alleviating symptoms and has shown highly promising preclinical results – five topical applications over two weeks have provided up to 15 months of symptom relief.

As part of its clinical development program, TIRmed Pharma is now working with Zelmic to establish GMP-compliant manufacturing processes for TIR-C. The extended collaboration includes both formulation and production of clinical trial material, focusing on product quality, stability, and regulatory compliance ahead of the planned Phase I study.

“The expanded partnership with Zelmic marks a milestone in the clinical development of TIR-C,” says Leo Holmgren, CEO of TIRmed Pharma. “Zelmic’s deep expertise in topical formulation development strengthens the foundation for our clinical program and supports our mission to improve treatment outcomes for patients with atopic dermatitis worldwide.”

“We are delighted to continue supporting TIRmed Pharma in developing this promising drug candidate,” says David Sagna, CEO of Zelmic. “Reliable manufacturing and analytical

processes are crucial to ensuring quality and consistency ahead of entering clinical development, and we look forward to contributing our formulation expertise to this important project.”

For more information, please contact:

Leo Holmgren, CEO

Phone: +46 70 049 18 42

Email: leo.holmgren@tirmedpharma.com

About TIRmed Pharma

TIRmed Pharma is a biotechnology company developing next-generation immunomodulatory therapies for autoimmune skin diseases, with an initial focus on atopic dermatitis (eczema). The company’s drug candidate, TIR-C, is a topical oligonucleotide-based treatment that regulates immune responses and targets the disease’s underlying mechanisms. Promising preclinical results support its potential to provide long-lasting relief and reduce treatment burden. Building on expertise in immunology and drug development, the company is pioneering new solutions in dermatological immunotherapy to enable more targeted and effective treatment options. TIRmed Pharma is headquartered in Stockholm, Sweden. For more information, visit tirmedpharma.com and follow TIRmed on [LinkedIn](#).

About Zelmic

Zelmic AB is a specialist CRO and CDMO focused on topical and transdermal drug development. Based in Lund, Sweden, the company offers end-to-end services from formulation and analytical development to IVRT/IVPT testing and GMP manufacturing of clinical materials. With deep expertise in semisolid formulations and regulatory compliance, Zelmic helps pharma and biotech partners turn topical drug concepts into effective, market-ready products. For more information, visit zelmic.se.